NeuBase Therapeutics, Inc.
NBSE · NASDAQ
9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 | |
|---|---|---|---|---|
| Market Cap | $12,832 | $98,575 | $148,918 | $41,276 |
| - Cash | $23,153 | $52,893 | $31,992 | $10,314 |
| + Debt | $5,996 | $6,542 | $139 | $123 |
| Enterprise Value | -$4,324 | $52,224 | $117,064 | $31,085 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$1,263 | -$576 | -$280 | -$128 |
| % Margin | – | – | – | – |
| EBITDA | -$32,924 | -$25,924 | -$17,227 | -$26,701 |
| % Margin | – | – | – | – |
| Net Income | -$34,235 | -$25,667 | -$17,261 | -$27,087 |
| % Margin | – | – | – | – |
| EPS Diluted | -21.08 | -18.8 | -17.6 | -65.49 |
| % Growth | -12.1% | -6.8% | 73.1% | – |
| Operating Cash Flow | -$29,012 | -$18,874 | -$10,710 | -$2,845 |
| Capital Expenditures | -$472 | -$1,438 | -$717 | -$553 |
| Free Cash Flow | -$29,484 | -$20,312 | -$11,427 | -$3,398 |